ReviewFrontiers in cardiovascular medicine2022
Transcatheter tricuspid valve interventions: Current status and future perspectives.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Transcatheter Tricuspid Valve Interventions to Manage Tricuspid Regurgitation: A Narrative Review.Reviews in cardiovascular medicine · 2025Review
- Caval Transcatheter Valve Implantation: An Alternate Transcatheter Approach to the Treatment of Severe Tricuspid Regurgitation.CASE (Philadelphia, Pa.) · 2025Article
- Transcatheter tricuspid valve replacement: will it prevail?Frontiers in cardiovascular medicine · 2025Review
- Article
- Efficacy and Safety of Cardioband in Patients with Tricuspid Regurgitation: Systematic Review and Meta-Analysis of Single-Arm Trials and Observational Studies.Journal of clinical medicine · 2024Review
- Tricuspid Regurgitation Complicating Heart Failure: A Novel Clinical Entity.Reviews in cardiovascular medicine · 2024Review
- The Right Coronary Anatomy and Operative Topography of the Tricuspid Valve Annulus.Journal of cardiovascular development and disease · 2024Article
- Cardiac Computed Tomography Screening for Tricuspid Transcatheter Annuloplasty Implantation.Circulation. Cardiovascular imaging · 2024Article
- Tricuspid regurgitation and heart failure: the fate of treated vs. untreated cohort in the percutaneous era.European heart journal. Imaging methods and practice · 2024Article
- Transcatheter Management of Tricuspid Regurgitation: A Review of Contemporary Evidence.Heart international · 2024Review
- Regulatory science promotes the translation of transcatheter tricuspid valve repair/replacement devices.Regenerative biomaterials · 2024Article
- Pharmacological Considerations during Percutaneous Treatment of Heart Failure.Current pharmaceutical design · 2024Review
- Structural Interventions in Heart Failure: Mending a Broken Heart.Journal of clinical medicine · 2023Review
- Case Report: Carcinoid heart disease with severe tricuspid regurgitation and concomitant patent foramen ovale causing severe hypoxia.Frontiers in cardiovascular medicine · 2023Article
- Procedural success of transcatheter annuloplasty in ventricular and atrial functional tricuspid regurgitation.Frontiers in cardiovascular medicine · 2023Article
- Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy.Global & regional health technology assessmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of transcatheter therapies to treat valvular heart diseases has changed the rules of the game, particularly in the case of aortic stenosis and mitral regurgitation. In the last years, the tricuspid valve has also been the focus of these percutaneous techniques for several reasons: (1) tricuspid regurgitation is a frequent disease associated with poor clinical outcomes in spite of medical treatment, leading to end-stage right ventricular heart failure, (2) surgical tricuspid valve repair or replacement has been the treatment of choice for patients with tricuspid valve disease, but high mortality rates for isolated surgical tricuspid valve intervention have been reported in the literature, and (3) most patients with tricuspid pathology are ultimately denied cardiac surgery because of their comorbidity burden. Thus, in this context the development of less invasive catheter-based therapies would be of high clinical relevance. The present review provides an overview regarding the framework of chronic tricuspid regurgitation transcatheter therapeutic options, summarizes the transcatheter systems under clinical use or clinical evaluation with their technical features, and describes the updated current evidence in this challenging and evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.